Investment objective & strategy
As of Jan. 28, 2026 · prospectusObjective. The investment objective of the Fund is long-term capital appreciation .
Strategy. The Fund seeks investments whose prices will increase over time. The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of health sciences companies, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the Health Care sector. The group of industries in which the Fund concentrates its investments is known as its sector. The term investable assets refers to the Fund's net assets plus any borrowings for investment purposes. The Fund's investable assets will be less than its total assets to the extent that it has borrowed money for … The Fund seeks investments whose prices will increase over time. The Fund normally invests at least 80% of its investable assets in equity and equity-related securities of health sciences companies, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the Health Care sector. The group of industries in which the Fund concentrates its investments is known as its sector. The term investable assets refers to the Fund's net assets plus any borrowings for investment purposes. The Fund's investable assets will be less than its total assets to the extent that it has borrowed money for non-investment purposes, such as to meet anticipated redemptions. The Fund invests in securities of issuers among a number of different countries throughout the world, one of which is the United States. The Fund has no limit on the amount of assets that must be invested in each country. However, the Funds investments in the securities of non-U.S. issuers, which are referred to as foreign securities and includes stocks and other equity-related securities, is limited to 35% of the Fund's total assets. The Fund participates in the initial public offering (IPO) market. Equity and equity-related securities in which the Fund primarily invests are common stocks, nonconvertible preferred stocks and convertible securities. The Fund holds those equity and equity-related securities in which the portfolio managers have a high level of conviction for outperformance in the intermediate and long term and believe have limited downside potential in the short term. The portfolio managers use fundamental and quantitative analyses to select individual securities.
Top holdings
As of Feb. 27, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| LILLY ELI and CO | — | $244.65M | 16.77% |
| (PIPA070) PGIM Core Government Money Market Fund | — | $112.60M | 7.72% |
| MERCK & CO | — | $87.78M | 6.02% |
| GILEAD SCIENCES INC | — | $63.72M | 4.37% |
| UNITEDHEALTH GRP | — | $62.81M | 4.31% |
| VERTEX PHARMACEUTICALS INC | — | $51.87M | 3.56% |
| CVS HEALTH CORP | — | $47.73M | 3.27% |
| LONZA GROUP -REG | — | $45.68M | 3.13% |
| ARGENX SE SPONSORED ADR | — | $45.28M | 3.10% |
| REGENERON PHARMACEUTICALS INC | — | $44.81M | 3.07% |
Portfolio moves
Nov 28, 2025 → Feb 27, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| HARTFORD HEALTHCARE HLS FUND · HIAHX, HBGHX | 44% | 0.93% |
| EQ/T.Rowe Price Health Sciences Portfolio | 43% | 0.95% |
| THE HARTFORD HEALTHCARE FUND · HGHAX, HGHCX, HGHYX, HGHIX, HGHRX, HGHSX, HGHTX, HGHFX, HGHVX | 43% | 0.94% |
Advisers
| Firm | Role |
|---|---|
| PGIM INVESTMENTS LLC | Adviser |
| Jennison Associates LLC | Sub-adviser |
Footnotes
- Expense ratio as of January 28, 2026, from the fund's prospectus.
- Net assets and holdings count as of February 27, 2026, from the fund's N-PORT filing.
- Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.